FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Pharma news

Jury rules against Merck in second NJ Vioxx trial

Tools

Merck has been handed a setback in a key Vioxx lawsuit. A New Jersey jury awarded $47.5 million for a plaintiff. It was the second time for the case to go to a jury. Merck won the first case, but an appeals court threw out the verdict after deciding that Merck had excluded new evidence that had later come to light. The jury decided that Merck had committed consumer fraud and had intentionally suppressed or concealed material information from physicians. Merck says it will appeal the decision as it faces thousands of suits from other plaintiffs alleging that Vioxx had harmed them.

- read the Irish Times' report on the trial

ALSO: Former CMS administrator Mark McClellan says that the safety issues surrounding Vioxx could have been discovered much sooner if the FDA had mined insurers' big drug databases for more information on drugs. Report

Related Articles:
Judge throws out $50M Vioxx award. Report
Merck faces long road in Vioxx battle. Report
Merck faces flood of new Vioxx suits. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter: